Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05360056

Continuous Glucose Monitoring Following Hospital Discharge

In this 12-week prospective observational cohort study, hospitalized insulin-requiring patients with T2D will receive a Dexcom continuous glucose monitor (CGM) to wear post-hospital discharge. Patients will complete surveys assessing patient-reported outcomes prior to CGM use and following completion of the study. CGM data will be captured by the patient smartphone app and analyzed. Patients will receive personalized CGM targets and alerts for hyperglycemia and hypoglycemia. Customized reports/ decision support will be sent to the usual diabetes provider. The initial observational cohort study design will be followed by an extension phase of 12 weeks in which data on continuation of use and glucose control will be collected but no further reports will be communicated to providers.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Type 2 Diabetes Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The Ohio State University Medical Center - Outpatient Care East

Columbus, Ohio, 43203, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Type 2 Diabetes
  • Basal insulin use >10 units per day
  • Hemoglobin A1c >8.0%
  • Smartphone compatible with Clarity App
  • Age ≥18 years

Exclusion criteria

  • Type 1 DM
  • Inability to consent
  • Pregnancy
  • Prisoners
  • Discharge to skilled nursing facility

Treatment and study plan

Dexcom G6

Device

Wearable continuous glucose monitor

Primary outcomes

  1. Change in TIR 70-180 mg/dl

    Time frame: 12 weeks

    Change in %time in range between 70-180 mg/dl from 2 weeks to 12 weeks.

  2. % Wear Time >70%

    Time frame: 12 weeks

    The number of participants with % wear time >70% will be reported.

  3. DTSQc Score

    Time frame: 12 weeks

    The DTSQc compares the experience of the current treatment with the experience of the treatment before initiation of the study. Scores range from +3 ("much more satisfied now") to -3 ("much less satisfied now"), with 0 (midpoint) representing no change. Higher scores on the DTSQ total score indicate higher treatment satisfaction, and lower scores indicate lower treatment satisfaction. The total score ranges from -18 (maximum deterioration in satisfaction) to +18 (maximum improvement in satisfaction).A score of 0 indicates no change in satisfaction.

Sponsors and collaborators

Lead sponsor

Kathleen Dungan

Other

Collaborators

  • DexCom, Inc.

Registry information

Official study title

Effect of Continuous Glucose Monitoring Following Hospital Discharge of Patients With Type 2 Diabetes

Important dates

Study start
2022
Primary completion
2024
Study completion
2027
First posted
May 4, 2022
Registry last updated
Jul 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.